Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
N/A
-72,449 Reduced 82.9%
14,946 $49,000
Q2 2023

Aug 14, 2023

BUY
N/A
41,859 Added 91.93%
87,395 $289,000
Q1 2023

May 15, 2023

BUY
N/A
1,107 Added 2.49%
45,536 $150,000
Q4 2022

Feb 14, 2023

BUY
$3.08 - $4.05 $136,841 - $179,937
44,429 New
44,429 $147,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Shay Capital LLC Portfolio

Follow Shay Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shay Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shay Capital LLC with notifications on news.